C57BL/6JCya-Oas2em1/Cya
Common Name
Oas2-KO
Product ID
S-KO-17570
Backgroud
C57BL/6JCya
Strain ID
KOCMP-246728-Oas2-B6J-VB
Status
When using this mouse strain in a publication, please cite “Oas2-KO Mouse (Catalog S-KO-17570) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Oas2-KO
Strain ID
KOCMP-246728-Oas2-B6J-VB
Gene Name
Product ID
S-KO-17570
Gene Alias
Oasl11
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 5 (Mouse)
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Transcript ID
ENSMUST00000081491
NCBI Transcript ID
NM_001347448.1
Target Region
Exon 2
Size of Effective Region
~1.1 kb
Overview of Gene Research
Oas2, short for 2'-5'-oligoadenylate synthetase 2, is an interferon (IFN)-induced antiviral enzyme. It belongs to the OAS family, which also includes OAS1, OAS3, and OAS-like (OASL). Oas2 can generate 2'-5'-linked oligoadenylates upon activation by double-stranded RNA, which is involved in the RNA cleavage pathway and antiviral response system [6,8].
In breast cancer, high Oas2 mRNA expression is associated with favorable prognosis, potentially making it a prognostic biomarker [1]. In psoriasis, Oas2 is overexpressed in lesional skin and serum, and its expression is downregulated by biologics. Silencing Oas2 inhibits keratinocyte proliferation by regulating the cell cycle and suppressing IFN-1-induced phosphorylation of Jak1 and signal transducer and activator of transcription 1, suggesting it may be a therapeutic biomarker [2]. In SARS-CoV-2-related multisystem inflammatory syndrome in children, autosomal recessive deficiencies of Oas2 lead to excessive production of inflammatory cytokines upon viral stimulation, underlying the disease mechanism [3]. In mammary cancer, an activating mutation in Oas2 prevents pregnancy-driven metastases and enhances the effectiveness of checkpoint immunotherapy, establishing it as a therapeutic target [4]. In testicular cancer, upregulating Oas2 by piR-36249 and DHX36 inhibits cancer cell progression [5]. Oas2 also restricts intracellular Mycobacterium tuberculosis replication and enhances pro-inflammatory cytokine secretion [6], and inhibits Zika virus replication through activation of the Type Ι IFN signaling pathway [7].
In conclusion, Oas2 plays crucial roles in multiple disease conditions, including cancer, psoriasis, and infectious diseases. Its functions in these diseases range from being a prognostic biomarker, a therapeutic target, to being involved in the regulation of cell proliferation, cytokine production, and antiviral responses. Studies, especially those with potential loss-of-function models, have significantly contributed to our understanding of Oas2's role in these biological processes and disease conditions.
References：
1. Zhang, Yujie, Yu, Chaoran. 2020. Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer. In BMC cancer, 20, 575. doi:10.1186/s12885-020-07034-6. https://pubmed.ncbi.nlm.nih.gov/32560641/
2. Huang, Yan-Zhou, Zheng, Yu-Xin, Zhou, Yuan, Zheng, Min, Man, Xiao-Yong. 2022. OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augmenting IFN-1‒Induced Jak1‒Signal Transducer and Activator of Transcription 1 Phosphorylation in Psoriasis. In The Journal of investigative dermatology, 142, 2635-2645.e9. doi:10.1016/j.jid.2022.02.018. https://pubmed.ncbi.nlm.nih.gov/35305973/
3. Lee, Danyel, Le Pen, Jérémie, Yatim, Ahmad, Zhang, Shen-Ying, Casanova, Jean-Laurent. 2023. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. In Science (New York, N.Y.), 379, eabo3627. doi:10.1126/science.abo3627. https://pubmed.ncbi.nlm.nih.gov/36538032/
4. Ho, Wing-Hong Jonathan, Law, Andrew M K, Masle-Farquhar, Etienne, Oakes, Samantha R, Ormandy, Christopher J. 2022. Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases. In Breast cancer research : BCR, 24, 31. doi:10.1186/s13058-022-01525-z. https://pubmed.ncbi.nlm.nih.gov/35505346/
5. Wang, Qianqian, Chen, Peize, Wang, Xiaorong, Song, Xiaoyuan, Sun, Fei. 2023. piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2. In Non-coding RNA research, 8, 174-186. doi:10.1016/j.ncrna.2022.12.004. https://pubmed.ncbi.nlm.nih.gov/36710986/
6. Leisching, Gina, Cole, Victoria, Ali, Aus T, Baker, Bienyameen. 2019. OAS1, OAS2 and OAS3 restrict intracellular M. tb replication and enhance cytokine secretion. In International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 80S, S77-S84. doi:10.1016/j.ijid.2019.02.029. https://pubmed.ncbi.nlm.nih.gov/30822544/
7. Liao, Xinzhong, Xie, He, Li, Shilin, Yang, Chunhui, Chen, Limin. 2020. 2', 5'-Oligoadenylate Synthetase 2 (OAS2) Inhibits Zika Virus Replication through Activation of Type Ι IFN Signaling Pathway. In Viruses, 12, . doi:10.3390/v12040418. https://pubmed.ncbi.nlm.nih.gov/32276512/
8. Koul, Amit, Deo, Soumya, Booy, Evan P, Genung, Matthew, McKenna, Sean A. 2019. Impact of double-stranded RNA characteristics on the activation of human 2'-5'-oligoadenylate synthetase 2 (OAS2). In Biochemistry and cell biology = Biochimie et biologie cellulaire, 98, 70-82. doi:10.1139/bcb-2019-0060. https://pubmed.ncbi.nlm.nih.gov/30965010/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
